Skip to contentS
Skye Bioscience, Inc.
S
SKYESkye Bioscience, Inc. Released Aug 7, 2023, after the close
10-Q filed Aug 7, 2023, 38 days after period end · 0001516551-23-000044
Q2 2023 · 10-Q
Revenue—
Net Income-$3.11M-$3.11MN/M vs Q2 2022N/M vs Q1 2023 EPS Diluted
No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR
-$0.80-$0.80N/M vs Q2 2022N/M vs Q1 2023 Operating Income-$2,842,997N/M Operating Cash Flowderived-$1,991,836N/M Free Cash Flowderived-$1,991,836N/M Filing lag
ended Jun 30, 2023 · filed Aug 7, 2023 · 38 d after period end